- Home
- CEV vs APLT Comparison
CEV vs APLT Comparison
Compare CEV & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEV
- APLT
- Stock Information
- Founded
- CEV 1999
- APLT 2016
- Country
- CEV United States
- APLT United States
- Employees
- CEV N/A
- APLT N/A
- Industry
- CEV Finance/Investors Services
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- CEV Finance
- APLT Health Care
- Exchange
- CEV Nasdaq
- APLT Nasdaq
- Market Cap
- CEV 67.8M
- APLT 69.0M
- IPO Year
- CEV N/A
- APLT 2019
- Fundamental
- Price
- CEV $9.47
- APLT $0.51
- Analyst Decision
- CEV
- APLT Buy
- Analyst Count
- CEV 0
- APLT 6
- Target Price
- CEV N/A
- APLT $6.10
- AVG Volume (30 Days)
- CEV 19.6K
- APLT 893.4K
- Earning Date
- CEV 01-01-0001
- APLT 08-13-2025
- Dividend Yield
- CEV 4.23%
- APLT N/A
- EPS Growth
- CEV N/A
- APLT N/A
- EPS
- CEV 0.36
- APLT N/A
- Revenue
- CEV N/A
- APLT $121,000.00
- Revenue This Year
- CEV N/A
- APLT $415.60
- Revenue Next Year
- CEV N/A
- APLT $1,323.96
- P/E Ratio
- CEV $29.36
- APLT N/A
- Revenue Growth
- CEV N/A
- APLT N/A
- 52 Week Low
- CEV $8.83
- APLT $0.30
- 52 Week High
- CEV $10.91
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- CEV 45.58
- APLT 61.88
- Support Level
- CEV $9.37
- APLT $0.47
- Resistance Level
- CEV $9.59
- APLT $0.53
- Average True Range (ATR)
- CEV 0.07
- APLT 0.03
- MACD
- CEV -0.01
- APLT 0.00
- Stochastic Oscillator
- CEV 34.24
- APLT 83.33
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.